Platelet size indexes (MPV, PLC-R, and FSC), RP %, and the exposure of activated GP IIb-IIIa and P-selectin after platelet activation with different agonists were measured in the control (without CHD/ACS, receiving no antiplatelet drugs), CHD (ASA + clopidogrel), and ASC (ASA + ticagrelor) groups of patients (for patient characteristics, see Appendix A, Table A1). This evidence concerns the gene SELP and coronary artery disorder.